Xtant Medical (NYSEAMERICAN:XTNT) Stock Crosses Above Two Hundred Day Moving Average – What’s Next?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $0.55. Xtant Medical shares last traded at $0.52, with a volume of 27,928 shares trading hands.

Analysts Set New Price Targets

Separately, Craig Hallum set a $1.50 price objective on Xtant Medical and gave the stock a “buy” rating in a research note on Friday, October 18th.

Xtant Medical Stock Down 3.3 %

The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42. The firm has a market cap of $79.29 million, a P/E ratio of -4.39 and a beta of 0.33.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings data on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%. The business had revenue of $27.94 million for the quarter.

Institutional Trading of Xtant Medical

A hedge fund recently raised its stake in Xtant Medical stock. Geode Capital Management LLC boosted its stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 515,006 shares of the medical device company’s stock after acquiring an additional 212,394 shares during the period. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 at the end of the most recent quarter. Institutional investors and hedge funds own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.